Cite

HARVARD Citation

    Sabado, R. et al. (n.d.). Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record